AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone studied for effects on fat metabolism. It is not an FDA-approved weight-loss medicine. Animal experiments gave researchers a reason to investigate it, but a larger human obesity trial did not show a significant weight-loss advantage over placebo. That gap between an interesting mechanism and a useful treatment is the key to understanding AOD-9604. [1][3]
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see AOD-9604 (2 mg Vial) Dosage Protocol, AOD-9604 (5 mg Vial) Dosage Protocol, and AOD-9604 (10 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
What is AOD-9604, and how does it work?
AOD9604 and AOD 9604 are alternative spellings. The compound contains amino acids 177 through 191 from the end of growth hormone, with an added tyrosine. It’s a fragment, not a replacement for the whole hormone. [2]
Researchers wanted to know whether the fragment could affect fat tissue without the growth-promoting and glucose-related effects of full growth hormone.
In a 14-day mouse experiment, AOD-9604 reduced weight gain in obese mice and increased fat oxidation, meaning the use of fat for energy. Researchers also observed changes consistent with lipolysis, or fat breakdown. In a separate cell assay within the same study, the fragment did not compete with full growth hormone for its receptor. These findings help explain the research interest, but they do not demonstrate fat loss in people. [3]
The exact molecular target remains uncertain. A claim that AOD-9604 selectively removes abdominal fat, preserves muscle or produces predictable body-composition changes goes further than this mechanism research can establish. [1]
Does AOD-9604 work for weight loss?
The human evidence does not establish it as an effective obesity treatment. Early reports described encouraging signals, but the larger OPTIONS trial failed to confirm a significant benefit. FDA’s December 2024 evaluation also highlighted how little methodological detail was available for several earlier studies. [1]
| Research setting | What the evidence tells us |
|---|---|
| Mouse and cell experiments | Changes in fat oxidation, lipolysis and weight gain supported further research. They did not establish a human treatment effect. [3] |
| Earlier 12-week oral study, 300 adults | A conference abstract reported weight and waist changes. FDA found the reporting too limited to judge the findings confidently. [1] |
| OPTIONS trial, 502 adults randomized | The 24-week oral study included a diet and exercise program. Weight loss was not significantly better than placebo at the 12-week primary endpoint or at 24 weeks. [1] |
| Six-trial safety summary | Reported tolerability and monitored metabolic markers, not proof of effective weight loss or safety for every formulation and route. [2] |
Why do some accounts mention 536 participants?
The OPTIONS report described 536 people enrolled and 502 randomized. Those are different stages of trial participation, not two separate large studies. After the disappointing results, the developer announced in 2007 that it was ending development for obesity. [1]
Diet and exercise do not make the negative finding irrelevant. Both groups received that support; the comparison asked whether AOD-9604 added a benefit. Nor does a before-and-after photograph answer that question, because changes in food intake, activity and other treatments can contribute to the result.
What are the side effects and safety concerns?
A 2013 paper summarized six randomized trials and described a favorable overall tolerability profile. It reported no clinically important rise in IGF-1, no clear deterioration in glucose tolerance and no antibodies against AOD-9604 in the selected participants tested. The trials were funded by the developer, and the paper disclosed author financial or consulting relationships. [2]
Those findings need to be read alongside the adverse-event details and FDA’s later assessment:
- Headache and gastrointestinal symptoms: headache, diarrhea and flatulence appeared in the oral-study reports. A serious diarrhea event was considered possibly related to treatment.
- Intravenous-study events: one episode of severe chest tightness and some reports of euphoria were considered possibly related.
- Unresolved longer-term questions: cancers were diagnosed in some participants in one study. Investigators judged them unrelated, but FDA found the details insufficient to resolve causality. The reports do not establish that AOD-9604 causes cancer, and they also do not establish long-term safety.
Study size, duration and incomplete reporting limit what can be concluded about the side effect profile. [1]
Oral studies are not evidence for every injection product
The human research reviewed by FDA mainly involved oral or intravenous administration. Its 2024 assessment did not identify human exposure information for the proposed subcutaneous or transdermal uses. Changing the route changes the evidence question; an oral study cannot validate a different injectable product. [1]
FDA also flags potential immune reactions, peptide-related impurities and difficulties characterizing the active ingredient in compounded AOD-9604. A claim of high purity is not a clinical safety study. [4]
Is AOD-9604 FDA-approved?
No. AOD-9604 does not have an FDA-approved therapeutic indication or prescribing label. FDA’s compounding evaluation is a separate process from approval of a finished medicine, and a nomination or its withdrawal should not be described as drug approval. [1][4]
What about the GRAS claim?
The 2013 paper described an expert-panel conclusion concerning intended food uses. GRAS, short for generally recognized as safe, concerns safety under specified food-use conditions. It is not FDA approval to inject a substance or use it to treat obesity. [2][5]
Can competitive athletes use it?
WADA’s 2026 Prohibited List explicitly names AOD-9604 under growth hormone fragments in section S2.2.3. It is prohibited both in and out of competition. Athletes should check their governing body’s rules rather than rely on a product’s research label. [6]
Common questions about AOD-9604
How long does it take to work?
There is no dependable evidence-based timeline for meaningful weight loss. The larger study did not demonstrate a significant advantage at either 12 or 24 weeks, so a promise of results within a few weeks is not supported by that trial. [1]
What is the correct AOD-9604 dosage?
There is no approved therapeutic dose. The research used particular formulations, routes and monitored populations. Converting those experiments into a general injection schedule would skip important unanswered questions about exposure, effectiveness and safety. [1]
Is it similar to semaglutide or a GLP-1 medicine?
No. It is a growth hormone fragment, not a GLP-1 receptor agonist. FDA’s review distinguishes the investigational AOD-9604 evidence from approved obesity medicines, including specific semaglutide and tirzepatide products. They are not interchangeable. [1]
Quick check: does a well-tolerated study prove a medicine works?
No. Safety monitoring and effectiveness answer different questions. A trial can find similar rates of reported symptoms between groups without demonstrating a meaningful benefit. For AOD-9604, keep the tolerability findings separate from the unsuccessful larger weight-loss trial. [1][2]
Bottom line: AOD-9604 has a research history, not an established role as a weight-loss therapy. If weight management is the concern, discuss the cause, treatment goals and evidence-backed options with a qualified healthcare professional.
References
- U.S. Food and Drug Administration. AOD-9604 evaluation for the Pharmacy Compounding Advisory Committee. December 2024. Clinical effectiveness and safety assessment.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3:7-15. Developer-funded trial summary.
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25:1442-1449.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. AOD-9604 entry.
- U.S. Food and Drug Administration. About the GRAS notification program. Food-use regulatory explanation.
- World Anti-Doping Agency. The 2026 Prohibited List. Section S2.2.3.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.
Matching dosage protocols
Related protocols and comparisons
Further research context